Prof. Dr. Konrad Stopsack
- Department: Epidemiological Methods and Etiological Research
- Unit: no unit
Professor Dr. Konrad Stopsack, MPH has been leading the Department of Epidemiological Methods and Etiological Research since January 2025.
Konrad Stopsack studied epidemiology and biostatistics at the Harvard School of Public Health in Boston, USA, and completed his postdoctoral training in cancer epidemiology at the Memorial Sloan Kettering Cancer Center in New York, USA. His clinical training includes a medical degree with a doctorate from the University of Freiburg and a residency in internal medicine at the Mayo Clinic in Rochester, Minnesota, USA. Before his appointment at the University of Bremen, he held a tenure-track position in the Clinical and Translational Epidemiology Unit at Massachusetts General Hospital of the Harvard Medical School and in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health, where he continues to serve as an Adjunct Professor of Epidemiology.
His applied research focuses on the etiology of chronic diseases, particularly cancer, precancerous conditions, and cardiovascular disease. This research integrates the complex spectrum of causes of chronic diseases, from inherited genetic factors and modifiable lifestyle factors to structural factors. The planning, implementation, and evaluation of population-based and clinical cohort studies are central to the success of this research. Many studies rely on biobanks and tissue banks and employ methods of molecular epidemiology. Special emphasis is placed on prostate cancer and clonal hematopoiesis. Beyond etiological studies, Konrad Stopsack is involved in epidemiologic and clinical studies on risk prediction, improved diagnostic methods, and survival.
Advancing epidemiologic methods is Dr. Stopsack’s second focus. One area are methods to improve planning, conduct, and evaluation of biomarker studies using high-dimensional data generated by sequencing methods, multiplex protein assays, transcriptome assays, and artificial intelligence techniques. The ultimate goal is to reduce information bias and selection bias. Another area of interest is on more interpretable estimands in epidemiological and clinical studies. His research on how to conduct epidemiologic analyses in a more reproducible and more efficient manner includes structural approaches and data science methodologies, including developing and advancing open-source analysis software.
In additional roles, Dr. Stopsack is co-leader of the international Prostate Cancer Cohort Consortium (PC3), investigator in the Health Professionals Follow-up Study, and one of the editors of the European Journal of Epidemiology. His research projects have been supported by the National Cancer Institute, the National Institute of Aging, the Congressionally Directed Medical Research Program, the Prostate Cancer Foundation, and the Harvard–MIT Bridge Project.
Konrad Stopsack studied epidemiology and biostatistics at the Harvard School of Public Health in Boston, USA, and completed his postdoctoral training in cancer epidemiology at the Memorial Sloan Kettering Cancer Center in New York, USA. His clinical training includes a medical degree with a doctorate from the University of Freiburg and a residency in internal medicine at the Mayo Clinic in Rochester, Minnesota, USA. Before his appointment at the University of Bremen, he held a tenure-track position in the Clinical and Translational Epidemiology Unit at Massachusetts General Hospital of the Harvard Medical School and in the Department of Epidemiology at the Harvard T.H. Chan School of Public Health, where he continues to serve as an Adjunct Professor of Epidemiology.
His applied research focuses on the etiology of chronic diseases, particularly cancer, precancerous conditions, and cardiovascular disease. This research integrates the complex spectrum of causes of chronic diseases, from inherited genetic factors and modifiable lifestyle factors to structural factors. The planning, implementation, and evaluation of population-based and clinical cohort studies are central to the success of this research. Many studies rely on biobanks and tissue banks and employ methods of molecular epidemiology. Special emphasis is placed on prostate cancer and clonal hematopoiesis. Beyond etiological studies, Konrad Stopsack is involved in epidemiologic and clinical studies on risk prediction, improved diagnostic methods, and survival.
Advancing epidemiologic methods is Dr. Stopsack’s second focus. One area are methods to improve planning, conduct, and evaluation of biomarker studies using high-dimensional data generated by sequencing methods, multiplex protein assays, transcriptome assays, and artificial intelligence techniques. The ultimate goal is to reduce information bias and selection bias. Another area of interest is on more interpretable estimands in epidemiological and clinical studies. His research on how to conduct epidemiologic analyses in a more reproducible and more efficient manner includes structural approaches and data science methodologies, including developing and advancing open-source analysis software.
In additional roles, Dr. Stopsack is co-leader of the international Prostate Cancer Cohort Consortium (PC3), investigator in the Health Professionals Follow-up Study, and one of the editors of the European Journal of Epidemiology. His research projects have been supported by the National Cancer Institute, the National Institute of Aging, the Congressionally Directed Medical Research Program, the Prostate Cancer Foundation, and the Harvard–MIT Bridge Project.
EPI224 Cancer Prevention (Harvard T.H. Chan School of Public Health)
EpiStat2: Master Epidemiology (University of Bremen)
EpiStat2: Master Epidemiology (University of Bremen)
The responsibility for the content of this page lies with Konrad Stopsack.
